[go: up one dir, main page]

MA46062A - Traitement par ascaroside de l'oesophagite à éosinophiles - Google Patents

Traitement par ascaroside de l'oesophagite à éosinophiles

Info

Publication number
MA46062A
MA46062A MA046062A MA46062A MA46062A MA 46062 A MA46062 A MA 46062A MA 046062 A MA046062 A MA 046062A MA 46062 A MA46062 A MA 46062A MA 46062 A MA46062 A MA 46062A
Authority
MA
Morocco
Prior art keywords
ascaroside
treatment
eosinophilic esophagitis
esophagitis
eosinophilic
Prior art date
Application number
MA046062A
Other languages
English (en)
Inventor
Andrea Choe
Frank C Schroeder
Paul W Sternberg
Original Assignee
Boyce Thompson Institute For Plant Res
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boyce Thompson Institute For Plant Res, California Inst Of Techn filed Critical Boyce Thompson Institute For Plant Res
Publication of MA46062A publication Critical patent/MA46062A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/62Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046062A 2016-08-25 2017-08-25 Traitement par ascaroside de l'oesophagite à éosinophiles MA46062A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662379651P 2016-08-25 2016-08-25

Publications (1)

Publication Number Publication Date
MA46062A true MA46062A (fr) 2019-07-03

Family

ID=61245393

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046062A MA46062A (fr) 2016-08-25 2017-08-25 Traitement par ascaroside de l'oesophagite à éosinophiles
MA046061A MA46061A (fr) 2016-08-25 2017-08-25 Traitement ascaroside de maladies auto-immunes et inflammatoires

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA046061A MA46061A (fr) 2016-08-25 2017-08-25 Traitement ascaroside de maladies auto-immunes et inflammatoires

Country Status (5)

Country Link
US (4) US11464810B2 (fr)
EP (2) EP3503904A4 (fr)
CN (1) CN109843309A (fr)
MA (2) MA46062A (fr)
WO (2) WO2018039593A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003007A2 (pt) 2011-08-08 2017-03-01 Boyce Thompson Intitute For Plant Res compostos de mólecula pequena que controlam nemátodos patogênicos de inseto e planta
WO2018039593A1 (fr) 2016-08-25 2018-03-01 California Institute Of Technology Traitement par ascaroside de l'oesophagite à éosinophiles
CN114423774B (zh) * 2019-05-17 2024-11-08 加利福尼亚技术学院 蛔苷衍生物和使用方法
WO2021007282A1 (fr) * 2019-07-08 2021-01-14 Boyce Thompson Institute For Plant Research, Inc. Compositions et procédés pour améliorer la croissance de plantes
CN113475629A (zh) * 2021-08-12 2021-10-08 广东省科学院动物研究所 蛔甙在制备提高S.carpocapsae All线虫产量制剂中的应用
CN113575770A (zh) * 2021-08-12 2021-11-02 广东省科学院动物研究所 蛔甙在制备促进S.carpocapsae All感染期线虫恢复发育制剂中的应用
CN113728978A (zh) * 2021-08-19 2021-12-03 云南省烟草公司玉溪市公司 蛔甙在制备H.bacteriophora H06感染期线虫恢复发育制剂中的应用
CN113796460B (zh) * 2021-08-19 2023-07-18 云南省烟草公司玉溪市公司 蛔甙在制备促进H.indica LN2感染期线虫恢复发育制剂中的应用
EP4514131A1 (fr) * 2022-04-29 2025-03-05 Ascribe Bioscience Inc. Libération modifiée d'ascarosides

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1018396A (en) 1911-08-07 1912-02-20 Oley L Ledington Culvert-mold.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
TW327125B (en) 1994-02-07 1998-02-21 Merck & Co Inc Composition and method for protecting against pine exhausted
WO1996019920A1 (fr) 1994-12-27 1996-07-04 Pfizer Pharmaceuticals Inc. Compositions utilisees pour traiter les infections des arbres par les nematodes
ES2302881T3 (es) 1997-07-29 2008-08-01 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
EA003147B1 (ru) 1998-12-18 2003-02-27 Дюпон Фармасьютикалз Компани N-уреидоалкилпиперидины в качестве модуляторов активности рецепторов хемокинов
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10163602A1 (de) 2001-12-21 2003-07-10 Alpha Biocare Gmbh Gebaeude 26 Mittel mit Nematoden und Plathelminthen zur Behandlung allergischer Erkrankungen
KR100700884B1 (ko) 2002-11-14 2007-03-29 백융기 약학적으로 유용한 노화 및 스트레스 조절용 신규 페로몬 화합물 및 그 분리정제방법
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP2113246B1 (fr) 2003-08-07 2016-06-22 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR100556335B1 (ko) 2004-02-05 2006-03-03 정만길 6알-(3,6-디데옥시-엘-아라비노-헥소피라노실옥시)헵타노익산, 그 제조방법 및 그를 포함하는 장기휴면 유발효과
JP5063343B2 (ja) 2004-05-11 2012-10-31 バイエル・クロツプサイエンス・エル・ピー シロアリ防除方法
DE102006056544A1 (de) 2006-11-29 2008-06-05 Bayer Cropscience Ag Insektizide Wirkstoffkombinationen (Formononetin+Insektizide)
CA2679254A1 (fr) 2007-03-01 2008-09-04 Basf Se Melanges actifs pesticides comprenant des composes aminothiazoline
US8318146B1 (en) 2008-02-01 2012-11-27 The United States Of America, As Represented By The Secretary Of Agriculture Ascarosides as nematode sex pheromones
RU2513723C2 (ru) 2008-02-12 2014-04-20 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции
KR20090088496A (ko) 2008-02-15 2009-08-20 연세대학교 산학협력단 6-(3,6-디데옥시-α-L-아라비노-헥소피라노실옥시)헵타노익산 유도체 및 그 제조 방법
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
KR101210553B1 (ko) 2010-06-09 2012-12-10 연세대학교 산학협력단 신규한 당지질 유도체 화합물 및 이를 함유하는 혈관평활근세포 이상 증식 억제용 조성물
ES2894936T3 (es) * 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
EP2707379A4 (fr) 2011-05-13 2014-10-08 Glycosyn LLC Utilisation de 2'-fucosyllactose, 3-fucosyllactose et lactodifucotétraose purifiés en tant que prébiotiques
BR112014003007A2 (pt) 2011-08-08 2017-03-01 Boyce Thompson Intitute For Plant Res compostos de mólecula pequena que controlam nemátodos patogênicos de inseto e planta
AU2012294448A1 (en) 2011-08-08 2014-03-06 Boyce Thompson Institute For Plant Research Small molecule compounds for the control of nematodes
WO2013039872A1 (fr) * 2011-09-12 2013-03-21 Tufts Medical Center Compositions et procédés pour le traitement de maladies inflammatoires de l'intestin
US10136595B2 (en) 2013-03-15 2018-11-27 Boyce Thompson Institute For Plant Research, Inc. Compositions and methods for modulating immunity in plants
CA2907470C (fr) * 2013-03-15 2023-03-14 Boyce Thompson Institute For Plant Research, Inc. Compositions et procedes pour moduler l'immunite chez les vegetaux
WO2014151648A1 (fr) * 2013-03-15 2014-09-25 Coronado Biosciences, Inc. Traitement d'une maladie auto-immune au moyen de parasites helminthiques
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2018039593A1 (fr) 2016-08-25 2018-03-01 California Institute Of Technology Traitement par ascaroside de l'oesophagite à éosinophiles
CN114423774B (zh) 2019-05-17 2024-11-08 加利福尼亚技术学院 蛔苷衍生物和使用方法
WO2020247480A1 (fr) 2019-06-03 2020-12-10 Holoclara, Inc. Compositions et méthodes d'administration de microbiote de mammifère

Also Published As

Publication number Publication date
WO2018039593A9 (fr) 2018-05-03
CN109843309A (zh) 2019-06-04
US20230026686A1 (en) 2023-01-26
EP3503903A1 (fr) 2019-07-03
US11077151B2 (en) 2021-08-03
WO2018039593A1 (fr) 2018-03-01
EP3503904A1 (fr) 2019-07-03
EP3503903A4 (fr) 2020-03-25
MA46061A (fr) 2019-07-03
EP3503904A4 (fr) 2020-03-25
US20190175663A1 (en) 2019-06-13
US20190192578A1 (en) 2019-06-27
WO2018039591A1 (fr) 2018-03-01
US11464810B2 (en) 2022-10-11
US20220016182A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
MA46062A (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
EP3904937A4 (fr) Système de microscope
EP3430731A4 (fr) Architecture d'iugw
EP3388004A4 (fr) Instrument de traitement
EP3409744A4 (fr) Agent de traitement de surface
FR3036037B1 (fr) Harnais d'encordement perfectionne
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
EP3564335A4 (fr) Agent de traitement de surface
EP3757187A4 (fr) Agent de traitement de surface
EP3298448A4 (fr) Microscope optogénétique
EP3431566A4 (fr) Agent de traitement de surface
EP3988986A4 (fr) Système de microscope
EP3858943A4 (fr) Agent de traitement de surface
DK3463269T3 (da) Hånddesinfektionsmiddel
EP3448263A4 (fr) Traitement électrothérapeutique
EP3375108A4 (fr) Traitement dewlan
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL256103B (en) Compositions and methods for treating celiac sprue disease
EP3468548A4 (fr) Méthodes de traitement du cancer du pancréas
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
EP3351561A4 (fr) Dérivé d'adrénomédulline à action prolongée
EP3431808A4 (fr) Butée d'arrêt